content

Proprietary Nasal Delivery Formulation of Diazepam Developed by Particle Sciencesโ€™ Reaches NDA

Proprietary nasal delivery formulation of diazepam for the treatment of epilepsy developed by CDMO, Particle Sciences, a Lubrizol LifeSciences company, has been submitted as...

Recro Gainesville Adds New Facility, Broadens Capabilities With High-Potent Processing on Deck

Recro Gainesville has added a 24,000-square-foot facility, which includes high-potent material processing space, near its existing 97,000-square-foot contract pharmaceutical development and manufacturing plant. ...

bioLIVE to merge with BioProduction Congress for 2019 event

bioLIVE โ€“ the bioprocessing and manufacturing event running adjacent to CPhI Worldwide โ€“ will next year incorporate BioProduction Congress to become bioLIVE at CPhI...

Thermo Fisher Scientific launches mass spectrometry software to accelerate small-molecule characterization

Pharmaceutical scientists are now able to overcome challenges associated with the identification and characterization of small molecules and their fragments with Thermo Scientific Mass...

Record growth at The Wasdell Group

The Wasdell Group , a leading outsourcing partner for the pharmaceutical, medical device and clinical development and manufacturing industries, has experienced over 40% revenue...

Clinerion expands team and moves to new headquarters in Basel

Clinerionโ€™s move to new headquarters is driven by growth in its business and its team, and matches the expansion in its international network of...

Proprietary nasal delivery formulation of diazepam developed by particle sciences’ reaches NDA

The Lubrizol Corporation announces a proprietary nasal delivery formulation of diazepam for the treatment of epilepsy which was developed by contract development and manufacturing...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read